Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19
NCT ID: NCT04569383
Last Updated: 2021-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2020-10-05
2021-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to assess the safety and tolerability of the candidate vaccine and to characterize its immunogenicity.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
15 participants will receive 10\^7 infectious units (IU) of MVA-SARS-2-S on days 0 and 28.
15 participants will receive 10\^8 IU of MVA-SARS-2-S on days 0 and 28. Safety and immunogenicity data will be collected throughout the study, which concludes at day 168.
A subgroup will receive a heterologous booster vaccination with a licensed COVID-19 vaccine. Vaccinees will receive two doses of the Comirnaty vaccine (21 days interval).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1x10E7 IU (low dose)
1x10E7 IU MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
MVA-SARS-2-S vaccinations (days 0 & 28)
Vaccination with MVA-SARS-2-S in two escalating dose regimens
Comirnaty
Vaccination with Comirnaty (21 day interval)
1x10E8 IU (high dose)
1x10E8 MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
MVA-SARS-2-S vaccinations (days 0 & 28)
Vaccination with MVA-SARS-2-S in two escalating dose regimens
Comirnaty
Vaccination with Comirnaty (21 day interval)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MVA-SARS-2-S vaccinations (days 0 & 28)
Vaccination with MVA-SARS-2-S in two escalating dose regimens
Comirnaty
Vaccination with Comirnaty (21 day interval)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy male and female adults aged 18-55 years
* No clinically significant health problems as determined during medical history and physical examination at screening visit
* Body mass index 18.5 - 30.0 kg/m2 and weight \> 50 kg at screening
* Adults male or non-pregnant, non-lactating female with negative pregnancy test
* Males and females who agree to comply with the applicable contraceptive requirements of the protocol
1. Ability to understand the subject information and to personally name, sign and date the in-formed consent to participate in the study.
2. Provided written informed consent.
3. Continues to be in stable health condition as determined during medical history and physi-cal examination on vaccination visits.
4. Non-pregnant, non-lactating female with a negative pregnancy test at screening and on dosing days (prior to vaccination).
5. Be willing to refrain from blood donation during the course of the study.
6. The subject is co-operative and available for the entire study.
7. Need to have participated in previous part of the MVA-SARS-2-S vaccine study (Eudra-CT No: 2020-002998-10)
Exclusion Criteria
* Receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination
* Previous rMVA immunization
* Known allergy to the components of the SARS-CoV-2 vaccine product
* Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine
* Evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product
* Clinically relevant findings in ECG
* Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes
* Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child
1. Prior infection with SARS-CoV-2 in medical history (documented by PCR test)
2. Receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination.
3. Receipt any COVID-19 vaccine (investigational or licensed other than MVA-SARS-2-S be-fore vaccination throughout end of study).
4. Known allergy to the components of t Comirnaty®.
5. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine.
6. Participation in a clinical trial other than the MVA-SARS-2-S vaccine trial or use of an in-vestigational product other than MVA-SARS-2-S within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study.
7. Evidence in the subject's medical history or in the medical examination that might influence
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Center for Infection Research
OTHER
Philipps University Marburg
OTHER
Ludwig-Maximilians - University of Munich
OTHER
Universitätsklinikum Hamburg-Eppendorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marylyn M Addo, MD
Role: PRINCIPAL_INVESTIGATOR
Universitätsklinikum Hamburg-Eppendorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf
Hamburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grewe I, Friedrich M, Dieck ML, Spohn M, Ly ML, Krahling V, Mayer L, Mellinghoff SC, Rottstegge M, Kraemer R, Volz A, Becker S, Fathi A, Dahlke C, Weskamm LM, Addo MM. MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity. Front Immunol. 2024 Dec 19;15:1500615. doi: 10.3389/fimmu.2024.1500615. eCollection 2024.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UKE-DZIF-SARS-CoV-2
Identifier Type: -
Identifier Source: org_study_id